Role of Interleukin-17F Gene Polymorphism in Susceptibility to Acute Myeloid Leukemia: Relation to Serum Level of IL-17

Abstract

Abstract Background The pathogenesis of acute myeloid leukemia (AML) is complex and not fully understood. A variety of interleukins have been shown to regulate the survival, growth, and apoptosis of leukemia cells. The IL-17 family includes interleukin-17F [rs763780; A7488G]. The IL-17F rs763780 polymorphism inhibits the wild-type IL-17F's activity and raises tumor susceptibility contributing to the emergence of certain tumor types including AML. Objectives This work aimed to study the relation between IL-17F gene polymorphism and susceptibility to AML and evaluated IL-17 plasma levels in AML with different IL-17F genotypes. Results There was no statistically significant difference in the distribution of different IL-17F genotypes between cases and controls. While the statistical comparison between both groups showed a significant difference with p-value <0.001 regarding IL-17 plasma level being higher in the case group with cutoff value >35 ng/L. Conclusion We concluded that IL-17 gene polymorphism doesn’t increase susceptibility to AML in Egyptian adults. IL-17 plasma level is an excellent diagnostic biomarker in AML patients.